兒童生長激素缺乏症市場 - 全球產業規模、佔有率、趨勢、機會和預測（按類型、按產品、按應用、按藥物、按配銷通路、按地區和競爭細分，2020-2030 年）

2024 年全球兒童生長激素缺乏症 (PGHD) 市場價值為 38.7 億美元，預計到 2030 年將達到 64.1 億美元，預測期內複合年成長率為 8.77%。該市場涵蓋了旨在治療兒童生長激素缺乏症的各種診斷工具和治療解決方案。由於基因異常、先天性問題、腦外傷和醫療副作用等因素導致的 PGHD 發生率不斷上升，持續增加了對荷爾蒙療法的需求。生物技術的進步促進了創新重組人類生長激素的發展，提高了治療效果和患者的依從性。值得注意的是，輝瑞和OPKO的每週一次的somatrogon注射於2022年獲得歐盟批准，這反映了治療創新的重大進步。此外，人們對合成荷爾蒙療法的認知和接受度不斷提高，以及特納氏症等疾病的盛行率不斷上升，進一步促進了市場的擴張。不斷成長的研發活動，加上支持性的監管環境和有針對性的治療可用性，使 PGHD 市場在全球範圍內實現持續成長。

關鍵市場促進因素

兒童生長激素缺乏症（PGHD）盛行率不斷上升

主要市場挑戰

生長激素治療費用高昂

主要市場趨勢

生物和生物相似藥生長激素療法

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球兒童生長激素缺乏症市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依類型（先天性生長激素缺乏症、後天性生長激素缺乏症、特發性生長激素缺乏症）
  • 依產品（粉末、溶劑）
  • 依應用（生長激素缺乏症、特發性身材矮小症、特納氏症、小於胎齡兒、普拉德-威利症候群、其他）
  • 按藥物（Genotropin、Humatrope、Norditropin Flexpro、其他）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美兒童生長激素缺乏症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲兒童生長激素缺乏症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第8章：亞太地區兒童生長激素缺乏症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美兒童生長激素缺乏症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東和非洲兒童生長激素缺乏症市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 13 章：全球兒童生長激素缺乏症市場：SWOT 分析

第 14 章：競爭格局

• Novo Nordisk A/S
• Eli Lily and Company
• Novartis AG
• Merck KgaA
• Pfizer Inc.
• Ferring BV
• Genentech Inc
• BioParteners GmbH
• LG Chem Ltd.
• Ipsen Pharma

第 15 章：策略建議

第16章調查會社について,免責事項

The Global Pediatric Growth Hormone Deficiency (PGHD) Market was valued at USD 3.87 billion in 2024 and is projected to reach USD 6.41 billion by 2030, growing at a CAGR of 8.77% during the forecast period. This market encompasses a wide range of diagnostic tools and therapeutic solutions aimed at managing growth hormone deficiency in children. The rising incidence of PGHD, caused by factors such as genetic abnormalities, congenital issues, brain trauma, and side effects of medical treatments, continues to increase demand for hormone-based therapies. Advancements in biotechnology have led to the development of innovative recombinant human growth hormones, improving both treatment efficacy and patient compliance. Notably, Pfizer and OPKO's once-weekly somatrogon injection received EU approval in 2022, reflecting a significant stride in therapeutic innovation. Moreover, increasing awareness and acceptance of synthetic hormone therapy, alongside the documented prevalence of conditions like Turner Syndrome, further contribute to the market's expansion. Growing R&D activity, combined with a supportive regulatory environment and targeted treatment availability, positions the PGHD market for sustained growth globally.

Key Market Drivers

Increasing Prevalence of Pediatric Growth Hormone Deficiency (PGHD)

The rising number of pediatric growth hormone deficiency cases is a major growth driver for the global PGHD market. This increase is largely attributable to genetic predispositions, premature births, and improved diagnostic capabilities. Children born with a family history of GHD or with low birth weight are more prone to hormonal imbalances, prompting early screening and treatment. Enhanced neonatal care has also improved survival rates of premature infants, many of whom later require hormonal support for growth. Additionally, broader access to genetic testing and heightened medical surveillance has led to earlier diagnosis and a higher number of treated cases. As awareness around PGHD grows, healthcare providers and caregivers are more proactive in seeking timely intervention, contributing to rising treatment demand.

Key Market Challenges

High Cost of Growth Hormone Therapy

The significant cost associated with growth hormone therapy remains a key challenge for market growth. These treatments often involve long-term regimens with regular injections, which can accumulate substantial expenses for families. In regions with limited insurance coverage or insufficient healthcare infrastructure, the affordability of such therapies becomes a major barrier. The high treatment cost can also deter therapy initiation or result in poor adherence, ultimately impacting patient outcomes and limiting market expansion, particularly in low- and middle-income countries.

Key Market Trends

Biological and Biosimilar Growth Hormone Therapies

A notable trend shaping the PGHD market is the increased adoption of biological and biosimilar hormone therapies. Biological products, produced using living cells, offer high specificity and therapeutic precision, while biosimilars provide a cost-effective alternative with similar clinical efficacy. The growing entry of biosimilars into the market has fostered greater competition, resulting in improved affordability and access. As biosimilars become more widely accepted, healthcare providers can tailor treatment regimens with a broader portfolio of therapeutic options, making hormone replacement therapy more accessible and personalized.

Key Market Players

• Novo Nordisk A/S
• Eli Lily and Company
• Novartis AG
• Merck KgaA
• Pfizer Inc.
• Ferring B.V
• Genentech Inc
• BioParteners GmbH
• LG Chem Ltd.
• Ipsen Pharma

Report Scope:

In this report, the Global Pediatric Growth Hormone Deficiency Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pediatric Growth Hormone Deficiency Market, By Type:

• Congenital GH Deficiency
• Acquired GH Deficiency
• Idiopathic GH Deficiency

Pediatric Growth Hormone Deficiency Market, By Product:

• Powder
• Solvent

Pediatric Growth Hormone Deficiency Market, By Application:

• Growth Hormone Deficiency
• Idiopathic Short Stature
• Turner Syndrome
• Small For Gestational Age
• Prader-Willi Syndrome
• Others

Pediatric Growth Hormone Deficiency Market, By Drug:

• Genotropin
• Humatrope
• Norditropin FlexPro
• Others

Pediatric Growth Hormone Deficiency Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Pediatric Growth Hormone Deficiency Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Growth Hormone Deficiency Market.

Available Customizations:

Global Pediatric Growth Hormone Deficiency market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Applications
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pediatric Growth Hormone Deficiency Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Congenital GH Deficiency, Acquired GH Deficiency, Idiopathic GH Deficiency)
  • 5.2.2. By Product (Powder, Solvent)
  • 5.2.3. By Application (Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small For Gestational Age, Prader-Willi Syndrome, Others)
  • 5.2.4. By Drug (Genotropin, Humatrope, Norditropin Flexpro, Others)
  • 5.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Pediatric Growth Hormone Deficiency Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Product
  • 6.2.3. By Application
  • 6.2.4. By Drug
  • 6.2.5. By Distribution Channel
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pediatric Growth Hormone Deficiency Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Drug
      • 6.3.1.2.5. By Distribution Channel
  • 6.3.2. Canada Pediatric Growth Hormone Deficiency Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Drug
      • 6.3.2.2.5. By Distribution Channel
  • 6.3.3. Mexico Pediatric Growth Hormone Deficiency Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Drug
      • 6.3.3.2.5. By Distribution Channel

7. Europe Pediatric Growth Hormone Deficiency Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Product
  • 7.2.3. By Application
  • 7.2.4. By Drug
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Drug
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. United Kingdom Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Drug
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. Italy Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Drug
      • 7.3.3.2.5. By Distribution Channel
  • 7.3.4. France Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Drug
      • 7.3.4.2.5. By Distribution Channel
  • 7.3.5. Spain Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Drug
      • 7.3.5.2.5. By Distribution Channel

8. Asia-Pacific Pediatric Growth Hormone Deficiency Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Product
  • 8.2.3. By Application
  • 8.2.4. By Drug
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Drug
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. India Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Drug
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. Japan Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Drug
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. South Korea Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Drug
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Australia Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Drug
      • 8.3.5.2.5. By Distribution Channel

9. South America Pediatric Growth Hormone Deficiency Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Product
  • 9.2.3. By Application
  • 9.2.4. By Drug
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pediatric Growth Hormone Deficiency Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Drug
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. Argentina Pediatric Growth Hormone Deficiency Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Drug
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. Colombia Pediatric Growth Hormone Deficiency Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Drug
      • 9.3.3.2.5. By Distribution Channel

10. Middle East and Africa Pediatric Growth Hormone Deficiency Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Product
  • 10.2.3. By Application
  • 10.2.4. By Drug
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pediatric Growth Hormone Deficiency Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Drug
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Saudi Arabia Pediatric Growth Hormone Deficiency Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Drug
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. UAE Pediatric Growth Hormone Deficiency Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Drug
      • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challanges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Pediatric Growth Hormone Deficiency Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Novo Nordisk A/S
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Eli Lily and Company
• 14.3. Novartis AG
• 14.4. Merck KgaA
• 14.5. Pfizer Inc.
• 14.6. Ferring B.V
• 14.7. Genentech Inc
• 14.8. BioParteners GmbH
• 14.9. LG Chem Ltd.
• 14.10.Ipsen Pharma

15. Strategic Recommendations

16. About Us & Disclaimer